financetom
Business
financetom
/
Business
/
Condom maker Church & Dwight sees FY forecasts at lower end as consumers turn cautious
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Condom maker Church & Dwight sees FY forecasts at lower end as consumers turn cautious
Aug 2, 2024 5:23 AM

Aug 2 (Reuters) - Church & Dwight ( CHD ) said on Friday

it expects full-year sales and profit at the lower end of its

previous forecast due to consumer hesitancy on spending for its

higher-priced household and personal care products.

Shares of the Trojan condom maker fell 4.3% in premarket

trade.

In a bid to defend their profit margins against higher

costs, consumer goods companies including Church & Dwight ( CHD ) have

been hiking their prices over the past two years, despite some

input expenses now declining.

While consumers have absorbed these hikes to buy the

company's products including Therabreath mouthwash and Xtra

liquid detergent, a sticky inflation has turned them more

cautious.

"Category consumption growth in both dollars and units has

moderated as the consumer remains under pressure," said CEO

Matthew Farrell in a statement.

The company saw consumption dollar growth slowing down to 2%

in eight main categories from 4.5% in the first 5 months of the

year, Farrell added.

The New Jersey-based company now expects full-year adjusted

profit growth to be at the lower end of the 8% to 9% range

projected earlier.

Annual organic sales are expected to grow by 4%, compared

with the previous forecast range of 4% to 5% increase.

However, the household products maker's second-quarter

revenue rose about 4% to $1.51 billion, in line with analysts'

estimates.

Excluding items, it earned 93 cents per share, beating the

LSEG expectations of 84 cents.

Volumes rose 3.5% in the quarter ended June 30, while

average selling prices climbed by only 1.2%. This helped the

adjusted gross margin climb 150 basis points to 45.4%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Osisko Development to Resume Activities at Cariboo Project in British Columbia After Wildfires
Osisko Development to Resume Activities at Cariboo Project in British Columbia After Wildfires
Jul 26, 2024
07:36 AM EDT, 07/26/2024 (MT Newswires) -- Osisko Development ( ODV ) said on Friday that it will resume activities at the Cariboo gold project in British Columbia after authorities lifted a wildfire evacuation order. The wildfires didn't affect mine site infrastructure and all access roads to the project are open, Osisko said, adding that it will continue to monitor...
Booz Allen Hamilton Fiscal Q1 Adjusted Earnings Fall, Revenue Rises; Fiscal 2025 Outlook Reaffirmed
Booz Allen Hamilton Fiscal Q1 Adjusted Earnings Fall, Revenue Rises; Fiscal 2025 Outlook Reaffirmed
Jul 26, 2024
07:31 AM EDT, 07/26/2024 (MT Newswires) -- Booz Allen Hamilton Holding ( BAH ) reported fiscal Q1 adjusted earnings Friday of $1.38 per diluted share, down from $1.47 a year earlier. Analysts polled by Capital IQ expected $1.52. Revenue for the quarter ended June 30 was $2.94 billion, compared with $2.65 billion a year earlier. Analysts surveyed by Capital IQ...
Balchem's Q2 Earnings, Net Sales Rise
Balchem's Q2 Earnings, Net Sales Rise
Jul 26, 2024
07:32 AM EDT, 07/26/2024 (MT Newswires) -- Balchem ( BCPC ) reported Q2 adjusted earnings Friday of $1.09 per diluted share, up from $1.06 a year earlier. Two analysts surveyed by Capital IQ expected $1.04. Net sales for the quarter ended June 30 was $234.1 million, compared with $231.3 million a year earlier. Three analysts surveyed by Capital IQ expected...
Akero Therapeutics Insider Sold Shares Worth $4,381,867, According to a Recent SEC Filing
Akero Therapeutics Insider Sold Shares Worth $4,381,867, According to a Recent SEC Filing
Jul 26, 2024
07:32 AM EDT, 07/26/2024 (MT Newswires) -- William Richard White, Chief Financial Officer, around July 23, 2024, sold 161,855 shares in Akero Therapeutics ( AKRO ) for $4,381,867. Following the Form 4 filing with the SEC, White has control over a total of 41,791 shares of the company, with 41,791 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1744659/000095017024086659/xslF345X03/ownership.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved